| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-485 | 1889279-16-6 | sc-507493 | 5 mg | $275.00 | ||
A-485 is an inhibitor of bromodomain-containing proteins. Its effects on gene expression could indirectly influence CDK2AP2-related pathways by altering the epigenetic landscape. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 is another bromodomain inhibitor that can disrupt gene transcription. Its action on gene expression could potentially intersect with CDK2AP2-mediated cellular processes. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a cyclin-dependent kinase inhibitor that primarily targets CDK2 and CDKIts impact on CDK2 activity might indirectly affect the regulatory role of CDK2AP2 in cell cycle progression. | ||||||
PHA-793887 | 718630-59-2 | sc-364580 sc-364580A | 5 mg 10 mg | $189.00 $432.00 | ||
PHA-793887 is a small molecule that inhibits several cyclin-dependent kinases, including CDKIts effects on CDK2 activity could have implications for CDK2AP2-regulated pathways. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a potent CDK inhibitor with activity against multiple CDKs, including CDKIts effects on CDK2 activity might have downstream consequences for CDK2AP2-mediated processes. | ||||||
P276-00 | 920113-03-7 | sc-477932 | 1 mg | $380.00 | ||
P276-00 is a cyclin-dependent kinase inhibitor that could potentially affect CDK2AP2-mediated pathways by targeting CDK2, a key player in the cell cycle. | ||||||